Model-Informed Drug Development (MIDD) has rapidly evolved, from a supportive tool to a core driver of decision-making across the entire drug development lifecycle. Backed by the draft ICH M15 guidance and compelling studies showing MIDD can save up to 10 months and $5 million per program, the value is no longer theoretical, it's transformational.

The Model-Informed Drug Development Summit, was a 3-day event featuring 20+ real-world case studies that showcase how MIDD is reshaping the industry.

Delegates discovered how to:

• Boost efficiency and reduce costs
• Mitigate risk across development stages
• Enhance product labeling for real-world impact

Whether you're optimizing existing MIDD strategies or evaluating its potential, this summit was the opportunity to join other pharmacometricians, clinical pharmacologists, and PKPD modelers and explore how MIDD can shift the benefit-risk balance in your favour.